Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06747936
PHASE3

A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282

Sponsor: Addpharma Inc.

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the efficacy and safetyof co-administration of AD-2281 and AD-2282 in patients with Primary Hypercholesterolemia

Official title: A Randomized, Double-blind, Active-controlled, Multi-center, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combined Administration of AD-2281 and AD-2282 in Patients With Primary Hypercholesterolemia.

Key Details

Gender

All

Age Range

19 Years - Any

Study Type

INTERVENTIONAL

Enrollment

129

Start Date

2025-02-03

Completion Date

2025-05-30

Last Updated

2026-08-27

Healthy Volunteers

No

Interventions

DRUG

AD-2281

PO, Once daily, 8weeks

DRUG

AD-2282

PO, Once daily, 8weeks

DRUG

Placebo of AD-2282

PO, Once daily, 8weeks

Locations (1)

Severance Hospital

Seoul, Seoul, South Korea